utide,aWeeklyGLP -1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes
暂无分享,去创建一个
J. Rosenstock | B. Charbonnel | G. Bolli | M. Boldrin | R. Balena | R. Ratner | B. Balas
[1] V. Aroda,et al. The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review , 2011, Diabetes/metabolism research and reviews.
[2] M. Culler,et al. Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. , 2010, Endocrinology.
[3] A. Astrup,et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.
[4] J. Rosenstock,et al. Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes , 2009, Diabetes Care.
[5] R. Berria,et al. Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone , 2009, Diabetes Care.
[6] R. Patterson,et al. Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes , 2009, Diabetes Care.
[7] B. Zinman,et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.
[8] D. Drucker,et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.